Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousTransplantation ChimeraBone MarrowTissue DonorsGraft vs Leukemia EffectWhole-Body IrradiationBone Marrow CellsPeripheral Blood Stem Cell TransplantationBusulfanLeukemiaHistocompatibilityTreatment OutcomeHistocompatibility TestingGraft SurvivalRecurrenceMyeloablative AgonistsGraft vs Tumor EffectRetrospective StudiesChimerismHematologic DiseasesLeukemia, Myeloid, AcuteAnemia, AplasticStem CellsMyelodysplastic SyndromesImmunosuppressive AgentsVidarabineRemission InductionCord Blood Stem Cell TransplantationLymphocyte TransfusionHLA AntigensHepatic Veno-Occlusive DiseasePrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsTransplantation, IsogeneicLiver TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSiblingsCombined Modality TherapyTransplantation ImmunologyTime FactorsSurvival RateHematopoiesisCytomegalovirus InfectionsSurvival AnalysisAcute DiseaseCyclophosphamideLymphocyte DepletionT-LymphocytesDisease-Free SurvivalSevere Combined ImmunodeficiencyMice, Inbred C57BLFollow-Up StudiesOpportunistic InfectionsMultiple MyelomaCystitisFlow CytometryMinor Histocompatibility AntigensLeukemic InfiltrationHematopoietic Stem Cell MobilizationLeukemia, MyeloidAntigens, CD34ImmunosuppressionKidney TransplantationNeoplasm, ResidualAntilymphocyte SerumSalvage TherapyLymphoproliferative DisordersBone and BonesGraft RejectionCell DifferentiationAntineoplastic Combined Chemotherapy ProtocolsCytomegalovirusImmunocompromised HostBlood Group IncompatibilityPrognosisFatal OutcomeBronchiolitis ObliteransRisk FactorsCyclosporineBone Marrow PurgingCytarabineCell TransplantationColony-Forming Units AssayMelphalanMesenchymal Stem Cell TransplantationMycosesPrimary MyelofibrosisLymphoma, Non-HodgkinRadiation ChimeraCell LineageGanciclovirGranulocyte Colony-Stimulating Factor